LucieFournier

Associate

Brussels + 32.2.645.15.47

Connect:

Share

Lucie Fournier works on European data protection and cybersecurity law, with a focus on implementing EU General Data Protection Regulation (GDPR) and ePrivacy Directive compliance. She advises multinational organizations in various industry sectors such as cloud computing, information and communications technology, telecom, cybersecurity, life sciences and health care, marketing, and financial services.

Lucie's practice includes advising clients on a variety of EU data protection and data security matters, such as the implementation of global data protection compliance projects, international transfers of personal data, and related advice (e.g., drafting data processing agreements with the new EU standard contractual clauses and supplementary measures, developing data transfer impact assessments, drafting binding corporate rules, etc.), data merging, profiling and social media compliance matters, advising on the use of cookies, handling data subject access requests, developing data protection impact assessments, and whistleblowing schemes.

Lucie has also recently been involved in assisting a multinational company on an international data localization project regarding the processing of personal and nonpersonal data.

Lucie also advises clients on data protection and cybersecurity issues in cross-border M&A transactions and investigations.

Prior to joining Jones Day, Lucie completed legal traineeships in the intellectual property and IT department of a U.S. law firm in Paris and at the French Ministry of Defense in Paris. She also has in-house experience as a legal adviser at a UK multinational company that focuses on defense, aerospace, and cybersecurity.

Experience

  • GfK sells European Consumer Panel (GfK CP) business to YouGovJones Day advised GfK SE in the €315 million sale of its European Consumer Panel business (GfK CP) to YouGov PLC, a leading international online research data and analytics technology group headquartered in the United Kingdom and listed on the London Stock Exchange (LSE: YOU).
  • Affiliate of Centre Lane Partners acquires appliance business from Instant BrandsJones Day advised an affiliate of Centre Lane Partners in the acquisition and financing of the appliances business of Instant Brands, designer and distributor of kitchen and home appliances, including the Instant Pot, pursuant to Section 363 of title 11 of the United States Code.
  • Riverside sells Guestline to Access GroupJones Day represented The Riverside Company in connection with the sale of portfolio company Guestline, a UK-based provider of mission critical software for the hospitality sector, to Access Group.
  • Labcorp completes spin-off of FortreaJones Day represented Labcorp (NYSE: LH), a leading global life sciences company, in the spin-off of Fortrea, the newly formed independent Contract Research Organization providing Phase I-IV clinical trial management, market access and technology solutions to pharmaceutical and biotechnology organizations around the world.
  • AAR acquires TraxJones Day advised AAR CORP. in the acquisition of Trax USA Corp., a leading independent provider of aircraft MRO and fleet management software, for a purchase price of $120 million in cash, plus up to a $20 million earn-out payment based on specified adjusted revenues in calendar year 2023 and 2024.
  • Orange and Masmovil to combine in €18.6 billion mergerJones Day is advising Orange, S.A. ("Orange"), one of the world's leading telecommunications operators, on the combination of their telecom business in Spain with Masmovil, one of the leading telecommunications operators in Spain, for an enterprise value of €18.6 billion (€7.8 billion for Orange Spain and €10.9 billion for Masmovil).
  • Consortium BelGaN Group BV acquires ON Semiconductor Belgium BVJones Day advised the consortium BelGaN Group BV with the acquisition of ON Semiconductor Belgium BV, a subsidiary of Semiconductor Components Industries, LLC, which designs and manufactures semiconductors components.
  • PTTGC acquires allnex from AdventJones Day advised PTT Global Chemical Public Company Limited in the €4 billion acquisition of allnex Holding GmbH from Advent International.
  • JBS acquires ViveraJones Day advised Brazilian JBS S.A., the world's largest protein company and second-largest food producer, in its acquisition of Vivera, Europe’s third-largest manufacturer of plant-based food, for an enterprise value of €341 million.
  • STERIS acquires Cantel Medical for $3.6 billionJones Day advised STERIS plc in its acquisition of Cantel Medical Corp, a global provider of infection prevention products and services primarily to endoscopy and dental customers, for $3.6 billion.
  • Sumitovant Biopharma acquires remaining stake in Urovant SciencesJones Day advised Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash.
  • Bombardier sells transportation business to Alstom for €6.2 billionJones Day served as antitrust and French corporate counsel in the €6.2 billion sale of Bombardier Inc.'s transportation business to Alstom S.A.
  • International chemicals producer conducts internal auditJones Day is advising an international chemicals producer in conducting a multi-national internal antitrust audit.
  • Milliken & Company acquires Borchers from The Jordan CompanyJones Day advised Milliken & Company in its acquisition of Borchers Group Limited, a global specialty chemicals company known for its innovative high-performance coating additives and specialty catalyst solutions, from The Jordan Company, L.P.
  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.
  • ICON acquires Symphony Clinical ResearchJones Day advised ICON plc as health care, clinical trial regulatory, and data privacy diligence counsel in its acquisition of Symphony Clinical Research, a leading provider of at-home patient and site support services.
  • Arsenal Capital Partners acquires HistoGeneX and Caprion BiosciencesJones Day advised Arsenal Capital Partners on major investments in HistoGeneX and Caprion Biosciences and the subsequent combination of the two businesses.
  • Evidera acquires MedimixJones Day advised Evidera, a business unit of Pharmaceutical Product Development, LLC, in its acquisition of Medimix International, a global technology company providing real-world evidence (RWE) insights and information to the pharmaceutical, diagnostic, and medical device industries.
    • View All

    February 2024 Newsletters

    EU Emergency Response Update – Key Policy & Regulatory Developments No. 112

    December 2023 Newsletters

    EU Emergency Response Update – Key Policy & Regulatory Developments No. 111

    November 2023 Newsletters

    EU Emergency Response Update – Key Policy & Regulatory Developments No. 110

    November 2023 Newsletters

    EU Emergency Response Update – Key Policy & Regulatory Developments No. 109

    November 2023 Newsletters

    EU Emergency Response Update – Key Policy & Regulatory Developments No. 108

    September 2023 Newsletters

    EU Emergency Response Update – Key Policy & Regulatory Developments No. 107

    September 2023 Newsletters

    EU Emergency Response Update – Key Policy & Regulatory Developments No. 106

    August 2023 Newsletters

    EU Emergency Response Update – Key Policy & Regulatory Developments No. 105

    July 2023 Newsletters

    EU Emergency Response Update – Key Policy & Regulatory Developments No. 104

    June 2023 Newsletters

    EU Emergency Response Update – Key Policy & Regulatory Developments No. 103
    View All

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.